Exosome-mediated delivery and regulation in neurological disease progression

Int J Biol Macromol. 2024 Apr;264(Pt 2):130728. doi: 10.1016/j.ijbiomac.2024.130728. Epub 2024 Mar 11.

Abstract

Exosomes (EXOs), membranous structures originating from diverse biological sources, have recently seized the attention of researchers due to their theranostic potential for neurological diseases. Released actively by various cells, including stem cells, adipose tissue, and immune cells, EXOs wield substantial regulatory influence over the intricate landscape of neurological complications, exhibiting both positive and negative modulatory effects. In AD, EXOs play a pivotal role in disseminating and breaking down amyloid-β protein. Moreover, EXOs derived from mesenchymal stem cells showcase a remarkable capacity to mitigate pro-inflammatory phenotypes by regulating miRNAs in neurodegenerative diseases. These vesicles possess the unique ability to traverse the blood-brain barrier, governing the aggregation of mutant huntingtin protein. Understanding the exosomal functions within the CNS holds significant promise for enhancing treatment efficacy in neurological diseases. This review intricately examines the regulatory mechanisms involving EXOs in neurological disease development, highlighting therapeutic prospects and exploring their utility in exosome-based nanomedicine for various neurological complications. Additionally, the review highlights the challenges associated with drug delivery to the brain, emphasizing the complexities inherent in this critical aspect of neurotherapeutics.

Keywords: BBB challenges; Diagnostic marker; Drug delivery; Exosomes; Neurological diseases; Therapeutic potential.

Publication types

  • Review

MeSH terms

  • Amyloid beta-Peptides / metabolism
  • Disease Progression
  • Exosomes* / metabolism
  • Humans
  • MicroRNAs* / genetics
  • Nervous System Diseases*

Substances

  • MicroRNAs
  • Amyloid beta-Peptides